Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients

Hypertension Research

Volumn 31, Issue 5, 2008, Pages 887-896

  Uno, Hideyuki ^a   Ishikawa, Joji ^a   Hoshide, Satoshi ^a   Kabutoya, Tomoyuki ^a   Ishikawa, Shizukiyo ^a   Shimada, Kazuyuki ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Amiodipine; Brain natriuretic peptide; Hypertensive targeted organ damage; Microalbuminuria; Strict blood pressure control

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HEART VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; KIDNEY INJURY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; ORGAN INJURY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; URINARY EXCRETION;

ALBUMINURIA; AMLODIPINE; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; C-REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HUMANS; HYPERTENSION; JAPAN; NATRIURETIC PEPTIDE, BRAIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 46049091172     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.887     Document Type: Article

References (42)

1. Chobanian AV, Bakris GL, Black HR, et al, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2571.
2. Whitworth JA: World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
3. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 356 (9246); 1955-1964.
4. Hozawa A, Ohkubo T, Kikuya M, et al: Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res 2002; 25: 57-63.
5. Matsubayashi K, Okumiya K, Wada T, Doi Y, Ozawa T: Home blood pressure control in Japanese hypertensive population. Lancet 1997; 350: 290-291.
6. Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R: Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601-605.
7. Ishikawa J, Kario K, Eguchi K, et al: Regular alcohol drinking is a determinant of masked morning hypertension detected by home blood pressure monitoring in medicated clinic blood pressure: the Jichi Morning Hypertension Research (J-MORE) Study. Hypertens Res 2006; 29: 679-686.
8. Verdecchia P, Reboldi G, Angeli F, et al: Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
9. Angeli F, Verdecchia P, Reboldi GP, et al: Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004; 17: 817-822.
10. Mehta JL, Lopez LM, Vachakis ND, et al: Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. Am Heart J 1993; 125: 1704-1710.
11. Donnelly R, Meredith PA, Miller SH, Howie CA, Elliott HL: Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther 1993; 54: 303-310.
12. Clavijo GA, de Clavijo IV, Weart CW: Amlodipine: a new calcium antagonist. Am J Hosp Pharm 1994; 51: 59-68.
13. Kuramoto K, Ichikawa S, Hirai A, Kanda S, Nakachi T, Ogihara T: Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-208.
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcome in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
15. Julius S, Kjeldsen SE, Weber M, et al, VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-2031.
16. Eguchi K, Kario K, Hoshide Y, et al: Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens 2004; 17: 112-117.
17. Stanton E, Hansen M, Wqijeysundera HC, Kupchak P, Hall C, Rouleau JL: PRAISE-2 study investigations: a direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed nonischemic origin. Eur Heart Fail 2005; 7: 557-565.
18. Wijeysundera HC, Hansen MS, Stanton E, et al, Praise II Investigators: Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am Heart J 2003; 146: 291-297.
19. Gerstein HC, Mann JF, Yi Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
20. Hillege HL, Fidler V, Diercks GF, et al: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
21. Imai Y, Otsuka K, Kawano Y, et al: Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771-782.
22. Anwar YA, Giacco S, McCabe EJ, Tendler BE, White WB: Evaluation of the efficacy of the Omron HEM-737 intel-lisense device for use on adults according to the recommendations of the Association for the Advancement of Medical Instrumentation. Blood Press Monit 1998; 3: 261-265.
23. Coleman A, Freeman P, Steel S, Shennan A: Validation of the Omron 7051T (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Press Monit 2006; 11: 27-32.
24. Yarows SA, Patel K, Brook R: Rapid oscillometric blood pressure measurement compared to conventional oscillometric measurement. Blood Press Monit 2001; 6: 145-147.
25. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
26. Sokoll LJ, Russell RM, Sadowski JA, Morrow FD: Establishment of creatinine reference values for older women. Clin Chem 1994; 40: 2276-2281.
27. Abernethy DR: Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. J Cardiovasc Pharmacol 1991; 17: s4-s7.
28. Osterloh IH: An update on the safety of amlodipine. J Cardiovasc Pharmacol 1991; 17: s65-s68.
29. Hosie J, Bremner AD, Fell PJ, James GV, Saul PA, Taylor SH: Side effects of dihydropyridine therapy: comparison of amlodipine and nifedipine retard. J Cardiovasc Pharmacol 1993; 22: s9-s12.
30. Bremner AD, Fell PJ, Hosie J, James IG, Saul PA, Taylor SH: Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. J Hum Hypertens 1993; 7: 79-81.
31. Bernink PJ, de Weerd P, ten CF, Remme WJ, et al: An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris. J Cardiovasc Pharmacol 1991; 17: s53-s56.
32. Varrone J: A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. Postgrad Med J 1991; 67: s28-s31.
33. Williams DM, Cubeddu LX: Amlodipine pharmacokinetics in healthy subjects. J Clin Pharmacol 1998; 28: 990-994.
34. Malacco E, Vari N, Capuano V, Spagnuolo V, Borgnino C, Palatini P: Val-Syst study: a randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003; 25: 2765-2780.
35. Pedrinelli R, Dell'Omo G, Melillo E, Mariani M: Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension 2000; 35: 621-625.
36. Frick MH, McGibney D, Tyler HM: A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med 1989; 225: 101-105.
37. Eguchi K, Kario K, Shimada K: Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res 2002; 25: 329-333.
38. Hamada T, Watanabe M, Kaneda T, et al: Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998; 80: 1453-1458.
39. Wang TJ, Larson MG, Levy D, et al: Plasma natriuretic peptide levels and risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
40. Ranieri G, Andriani A, Lamontanara G, De Cesaris R: Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension. Clin Pharmacol Ther 1994; 56: 323-330.
41. Yoshii T, Iwai M, Li Z, et al: Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative actions. Hypertens Res 2006; 29: 457-466.
42. Lewington S, Clarke R, Qizibach N, Peto R, Collins R: Prospective studies collaboration: age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.